{"organizations": [], "uuid": "c451a06e52792faf6e372150c365fa940c848b4c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180411.html", "section_title": "Archive News &amp; Video for Wednesday, 11 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-pixium-vision-launches-106-million/brief-pixium-vision-launches-10-6-million-euros-capital-increase-idUSFWN1RN0ZT", "country": "US", "domain_rank": 408, "title": "BRIEF-Pixium Vision Launches 10.6 Million Euros Capital Increase", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.847, "site_type": "news", "published": "2018-04-11T13:13:00.000+03:00", "replies_count": 0, "uuid": "c451a06e52792faf6e372150c365fa940c848b4c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pixium-vision-launches-106-million/brief-pixium-vision-launches-10-6-million-euros-capital-increase-idUSFWN1RN0ZT", "ord_in_thread": 0, "title": "BRIEF-Pixium Vision Launches 10.6 Million Euros Capital Increase", "locations": [], "entities": {"persons": [], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 11 (Reuters) - PIXIUM VISION SA:\n* LAUNCHES EUR 10.6 MILLION CAPITAL INCREASE * SUBSCRIPTION PRICE EUR 1.87 PER SHARE, A 35.07 PERCENT DISCOUNT\n* COMMITMENTS ALREADY RECEIVED FOR 94.13 PERCENT OF ISSUE * SUBSCRIPTION PERIOD: APRIL 17-26 INCLUDED\n* ADDITIONAL FINANCIAL RESOURCES WILL ALLOW FINALIZATION OF FEASIBILITY STUDY OF 5 PATIENTS IN THE US\n* THEY WILL ALSO PERMIT VALIDATION WITH FDA OF KEY STAGES OF CLINICAL PROGRAM IN THE US DURING H1 2019 Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-11T13:13:00.000+03:00", "crawled": "2018-04-12T14:11:44.014+03:00", "highlightTitle": ""}